Abstract
FabI, enoyl-ACP reductase (ENR), is the rate-limiting enzyme in the last step for fatty acids biosynthesis in many bacteria. Triclosan (TCL) is a commercial bactericide, and as a FabI inhibitor, it can depress the substrate (trans-2-enoyl-ACP) binding with FabI to hinder the fatty acid synthesis. The structure-activity relationship between TCL derivatives and FabI protein has already been acknowledged, however, their combination at the molecular level has never been investigated. This paper uses the computer-aided approaches, such as molecular docking, molecular dynamics simulation, and binding free energy calculation based on the molecular mechanics/Poisson-Bolzmann surface area (MM/PBSA) method to illustrate the interaction rules of TCL derivatives with FabI and guide the development of new derivatives. The consistent data of the experiment and corresponding activity demonstrates that electron-withdrawing groups on side chain are better than electron-donating groups. 2-Hydroxyl group on A ring, promoting the formation of hydrogen bond, is vital for bactericidal effect; and the substituents at 4-position of A ring, 2′-position and 4′-position of B ring benefit antibacterial activity due to forming a hydrogen bond or stabilizing the conformation of active pocket residues of receptor. While the substituents at 3′-position and 5′-position of B ring destroy the π-π stacking interaction of A ring and NAD+ which depresses the antibacterial activity. This study provides a new sight for designing novel TCL derivatives with superior antibacterial activity.
Similar content being viewed by others
References
Schäberle TF, Hack IM (2014) Overcoming the current deadlock in antibiotic research. Trends Microbiol 22:165–167
Payne DJ, Warren PV, Holmes DJ, Ji Y, Lonsdale JT (2001) Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov Today 6:537–544
Zhang Y-M, White SW, Rock CO (2006) Inhibiting bacterial fatty acid synthesis. J Biol Chem 281:17541–17544
Wright HT, Reynolds KA (2007) Antibacterial targets in fatty acid biosynthesis. Curr Opin Microbiol 10:447–453
Campbell JW, Cronan JE Jr (2001) Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu Rev Microbiol 55:305–332
Chirala SS, Huang W-Y, Jayakumar A, Sakai K, Wakil SJ (1997) Animal fatty acid synthase: functional mapping and cloning and expression of the domain I constituent activities. Proc Natl Acad Sci 94:5588–5593
Tsay J-T, Oh W, Larson T, Jackowski S, Rock C (1992) Isolation and characterization of the beta-ketoacyl-acyl carrier protein synthase III gene (fabH) from Escherichia coli K-12. J Biol Chem 267:6807–6814
Clough R, Matthis A, Barnum S, Jaworski J (1992) Purification and characterization of 3-ketoacyl-acyl carrier protein synthase III from spinach. A condensing enzyme utilizing acetyl-coenzyme A to initiate fatty acid synthesis. J Biol Chem 267:20992–20998
Waller RF, Keeling PJ, Donald RG, Striepen B, Handman E, Lang-Unnasch N, Cowman AF, Besra GS, Roos DS, McFadden GI (1998) Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc Natl Acad Sci 95:12352–12357
Gerusz V (2010) Recent advances in the inhibition of bacterial fatty acid biosynthesis. Annu Rep Med Chem 45:295–311
Heath RJ, Rock CO (1995) Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J Biol Chem 270:26538–26542
Heath RJ, Rock CO (2000) Microbiology: a triclosan-resistant bacterial enzyme. Nature 406:145–146
Miyakawa S, SUZUKI K, NOTO T, HARADA Y, OKAZAKI H (1982) Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice. J Antibiot 35:411–419
Baldock C, Rafferty JB, Sedelnikova SE, Baker PJ, Stuitje AR, Slabas AR, Hawkes TR, Rice DW (1996) A mechanism of drug action revealed by structural studies of enoyl reductase. Science 274:2107–2110
Rosner JL (1993) Susceptibilities of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid. Antimicrob Agents Chemother 37:2251–2253
Winder FG (1982) Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria. Biol Mycobacteria 1:353–438
McMurry LM, Oethinger M, Levy SB (1998) Triclosan targets lipid synthesis. Nature 39:4531–532
Heath RJ, Rubin JR, Holland DR, Zhang E, Snow ME, Rock CO (1999) Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J Biol Chem 274:11110–11114
Levy CW, Roujeinikova A, Sedelnikova S, Baker PJ, Stuitje AR, Slabas AR, Rice DW, Rafferty JB (1999) Molecular basis of triclosan activity. Nature 398:383–384
Qiu X, Janson CA, Smyth MG, Payne DJ, Abdel-Meguid SS (1999) Molecular basis for triclosan activity involves a flipping loop in the active site. Protein Sci 8:2529–2532
Ward WH, Holdgate GA, Rowsell S, McLean EG, Pauptit RA, Clayton E, Nichols WW, Colls JG, Minshull CA, Jude DA (1999) Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38:12514–12525
Kumar KR, Rohini P, Md AR, Devi YP (2015) A reviw on occurrence, fate and toxicity of triclosan. World J Pharm Pharm Sci 4:336–369
Nie Z, Perretta C, Lu J, Su Y, Margosiak S, Gajiwala KS, Cortez J, Nikulin V, Yager KM, Appelt K (2005) Structure-based design, synthesis, and study of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J Med Chem 48:1596–1609
Gerusz V, Denis A, Faivre F, Bonvin Y, Oxoby M, Briet S, LeFralliec Gr, Oliveira C, Desroy N, Raymond Cd (2012) From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria. J Med Chem 55:9914–9928
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612
Halgren TA, Nachbar RB (1996) Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J Comput Chem 17:587–615
Halgren TA (1996) Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J Comput Chem 17:520–552
Halgren TA (1996) Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. J Comput Chem 17:553–586
Halgren TA (1996) Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J Comput Chem 17:616–641
Goodsell DS, Morris GM, Olson AJ (1996) Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 9:1–5
Österberg F, Morris GM, Sanner MF, Olson AJ, Goodsell DS (2002) Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins: Struct, Funct, Bioinf 46:34–40
Morris GM, Huey R, Olson AJ (2008) Using autodock for ligand‐receptor docking. Curr Protoc Bioinformatics: 24:8.14.1-8.14. 40
Park H, Lee J, Lee S (2006) Critical assessment of the automated AutoDock as a new docking tool for virtual screening. Proteins: Struct, Funct, Bioinf 65:549–554
Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ (2010) Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discovery 5:597–607
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639–1662
Fuhrmann J, Rurainski A, Lenhof HP, Neumann D (2010) A new Lamarckian genetic algorithm for flexible ligand‐receptor docking. J Comput Chem 31:1911–1918
Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der Spoel D (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29:845–854
Acknowledgements
The authors acknowledge financial support from the National Natural Science Foundation of China. (No. 21176194, 21476174)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, X., Lu, J., Ying, M. et al. Docking and molecular dynamics studies on triclosan derivatives binding to FabI. J Mol Model 23, 25 (2017). https://doi.org/10.1007/s00894-016-3192-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00894-016-3192-9